Physician profile
Arvind Bhandari
NPI 1649212804
$10,416.85
in general payments reported to CMS, 2019-2025
23 companies · $563 in 2025
The $563 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,179 · 2020: $1,847 · 2021: $11.92 · 2022: $166 · 2023: $2,246 · 2024: $403 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,925 · Food and Beverage: $1,204 · Education: $83.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,925.00 |
| Food and Beverage | $1,204.35 |
| Education | $83.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $2,018.57 | 2019 | |
| Beigene USA, INC. | $1,925.00 | 2023 | Brukinsa |
| Celgene Corporation | $1,873.83 | 2020-2024 | Pomalyst |
| Janssen Biotech, INC. | $1,693.20 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Seagen INC. | $1,596.72 | 2019 | |
| Daiichi Sankyo INC. | $277.76 | 2025 | Datroway |
| Tempus Ai, INC | $167.09 | 2024 | |
| Taiho Oncology, INC. | $146.42 | 2023 | |
| Incyte Corporation | $122.30 | 2024 | Pemazyre |
| Novartis Pharmaceuticals Corporation | $104.88 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.95 | 2022 | |
| Apellis Pharmaceuticals, INC. | $83.46 | 2023 | Empaveli |
| Pfizer INC. | $60.67 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $53.72 | 2025 | Enhertu, Imfinzi |
| Merck Sharp & Dohme LLC | $34.18 | 2025 | Lynparza, Keytruda |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $28.05 | 2021-2023 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $25.24 | 2022 | |
| Exelixis INC. | $21.18 | 2024 | Cabometyx |
| Astellas Pharma US INC | $18.47 | 2025 | Xtandi |
| Coherus Oncology, INC. | $17.95 | 2024 | |
| Morphosys, US INC. | $16.94 | 2022 | |
| Cycle Pharmaceuticals INC | $15.73 | 2025 | Phyrago |
| Immunocore Limited | $14.54 | 2024 | Kimmtrak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Bhandari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.